Fortis Capital Advisors LLC Reduces Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• Fortis Capital Advisors LLC has reduced its stake in Regeneron Pharmaceuticals by 39.5%, now holding 1,011 shares valued at $641,000.
• Several large institutional investors have increased their positions in Regeneron, including Vanguard Group and Goldman Sachs, reflecting strong interest in the company.
• Regeneron reported earnings of $12.89 per share, exceeding estimates significantly, and acknowledged a 3.6% year-over-year revenue increase to $3.68 billion.

Fortis Capital Advisors LLC decreased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 39.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,011 shares of the biopharmaceutical company's stock after selling 660 shares during the quarter. Fortis Capital Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $641,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of REGN. Vanguard Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock valued at $5,966,767,000 after acquiring an additional 121,545 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Regeneron Pharmaceuticals by 4.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock worth $1,379,467,000 after acquiring an additional 89,579 shares during the period. Amundi boosted its position in shares of Regeneron Pharmaceuticals by 3.4% during the first quarter. Amundi now owns 1,603,901 shares of the biopharmaceutical company's stock worth $979,794,000 after buying an additional 52,166 shares during the period. Goldman Sachs Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 18.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after buying an additional 174,056 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its stake in shares of Regeneron Pharmaceuticals by 30.1% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock valued at $699,554,000 after acquiring an additional 226,952 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company's stock.

Regeneron Pharmaceuticals Trading Down 0.1%

Shares of Regeneron Pharmaceuticals stock opened at $555.83 on Thursday. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 1 year low of $476.49 and a 1 year high of $1,170.58. The company has a market capitalization of $58.91 billion, a P/E ratio of 14.01, a P/E/G ratio of 1.86 and a beta of 0.35. The business has a 50 day moving average price of $563.85 and a 200 day moving average price of $581.78.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its quarterly earnings data on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a return on equity of 15.06% and a net margin of 31.37%.The firm had revenue of $3.68 billion during the quarter, compared to the consensus estimate of $3.30 billion. During the same period in the previous year, the firm posted $11.56 EPS. The company's quarterly revenue was up 3.6% compared to the same quarter last year. Sell-side analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's payout ratio is 8.87%.

Analyst Upgrades and Downgrades

REGN has been the topic of a number of analyst reports. Argus cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Monday, June 30th. Citigroup reaffirmed a "buy" rating and set a $650.00 price objective on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Rothschild & Co Redburn started coverage on Regeneron Pharmaceuticals in a report on Thursday, August 14th. They set a "buy" rating and a $890.00 price target on the stock. BMO Capital Markets raised their price target on Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a report on Monday, August 4th. Finally, Truist Financial lowered their price target on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Three equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $817.67.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.